Importantly, some clinical research projects have shown that 4-hydroxytamoxifen and ICI 182,780 induce GPR30-mediated activation of downstream signaling pathways involved in the regulation of target gene expression and increase cell proliferation in a variety of cancer cells [293,299,300,301,302]. Here, GPER1 is linked to cancer.